Frequency of UTI in patients taking Empagliflozin versus Dapagliflozin in patients with type 2 diabetes Mellitus

Hatib Arshad; Ghulam Abbas Sheikh

doi:10.70749/ijbr.v3i5.1206

Authors

Hatib Arshad Department of Internal Medicine, Aziz Fatimah Hospital, Faisalabad, Punjab, Pakistan
Ghulam Abbas Sheikh Porfessor of Medicine, Aziz Fatimah Hospital, Faisalabad, Punjab, Pakistan.

DOI:

https://doi.org/10.70749/ijbr.v3i5.1206

Keywords:

Diabetics, Dapagliflozin, Urinary Tract Infections

Abstract

Introduction: Individuals with diabetes are more likely than those without the disease to get a UTI. Determining the prevalence of genitourinary infections in individuals with type 2 diabetes receiving treatment with two SGLT-2 inhibitors (dapagliflozin and empagliflozin) was the aim of the current investigation. Future recommendations for medications that lessen UTIs will be made in order to lower morbidity in these people. Study Design: Randomized Controlled Trail. Settings: Department of Medicine, Aziz Fatima Hospital, Faisalabad. Materials & Methods: There were 90 (45 in each group) type 2 diabetes individuals of either gender who were older than 18 and using SGLT-2 inhibitors as monotherapy or combination therapy. Participants were excluded if they had gestational diabetes, had a UTI within the last three months, were pregnant or nursing. Those in group B received 25 mg of empagliflozin for three months, while those in group A received 10 mg of dapagliflozin. The patients were told to collect their urine midstream in a sterile urine bottle for analysis. Three months later, the results were documented in terms of UTI. Results: Patients in groups A and B had mean ages of 39.51 ± 10.22 and 40.31 ± 8.36 years, respectively. The majority of the 47 patients (52.22%) were in the 19–40 age range. With a male to female ratio of 1:1.4, 37 (41.11%) of the 90 patients were men and 53 (58.89%) were women. Three patients (6.67%) in Group A (dapagliflozin group) and fifteen (33.33%) in Group B (empagliflozin group) had UTIs on average (p-value = 0.0016). Conclusion: According to this study, people with type 2 diabetes mellitus who take empagliflozin have a higher incidence of UTIs than those who take dapagliflozin.

Downloads

Download data is not yet available.

References

Carey, I. M., Critchley, J. A., DeWilde, S., Harris, T., Hosking, F. J., & Cook, D. G. (2018). Risk of infection in type 1 and type 2 diabetes compared with the general population: A matched cohort study. Diabetes Care, 41(3), 513-521.

https://doi.org/10.2337/dc17-2131

Choi, J. B., Yoo, J. M., Lee, Y., Kim, J. W., Lee, S., Kim, H. Y., Lee, D. S., Ko, S., & Choe, H. (2020). Effect of the sodium-glucose Cotransporter 2 inhibitor, Dapagliflozin, on Genitourinary infection in an animal model of type 2 diabetes. International Neurourology Journal, 24(1), 21-28.

https://doi.org/10.5213/inj.1938220.110

Rabizadeh, S., Nakhjavani, M., & Esteghamati, A. (2019). Cardiovascular and renal benefits of SGLT2 inhibitors: A narrative review. International Journal of Endocrinology and Metabolism, 17(2).

https://doi.org/10.5812/ijem.84353

Ferwani, P., Maldar, A., Shah, N., Shah, P., & Chadha, M. (2022). Prevalence of bacterial urinary tract infection among patients with type 2 diabetes mellitus on sodium-glucose cotransporter-2 inhibitors: A prospective real-world setting study. Journal of the ASEAN Federation of Endocrine Societies, 37(2), 5-8.

https://doi.org/10.15605/jafes.037.02.04

Tat, V., & Forest, C. P. (2018). The role of SGLT2 inhibitors in managing type 2 diabetes. JAAPA, 31(6), 35-40.

https://doi.org/10.1097/01.jaa.0000533660.86287.04

Schorling, O. K., Clark, D., Zwiener, I., Kaspers, S., Lee, J., & Iliev, H. (2020). Pooled safety and tolerability analysis of Empagliflozin in patients with type 2 diabetes mellitus. Advances in Therapy, 37(8), 3463-3484.

https://doi.org/10.1007/s12325-020-01329-7

Khan, S., Hashmi, M. S., Rana, M. A., Zafar, G. M., Asif, S., Farooq, M. T., & Zahoor, S. (2022). Frequency of urinary tract infections in type 2 diabetic patients taking Dapagliflozin. Cureus.

https://doi.org/10.7759/cureus.21720

Uitrakul, S., Aksonnam, K., Srivichai, P., Wicheannarat, S., & Incomenoy, S. (2022). The incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using SGLT2 inhibitors: A real-world observational study. Medicines, 9(12), 59.

https://doi.org/10.3390/medicines9120059

Caro, M. K., Cunanan, E. C., & Kho, S. A. (2022). Incidence and factors associated with genitourinary infections among type 2 diabetes patients on SGLT2 inhibitors: A single retrospective cohort study. Diabetes Epidemiology and Management, 7, 100082.

https://doi.org/10.1016/j.deman.2022.100082

Xu, B., Li, S., Kang, B., & Zhou, J. (2022). The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovascular Diabetology, 21(1).

https://doi.org/10.1186/s12933-022-01512-w

Yang, H., Choi, E., Park, E., Na, E., Chung, S. Y., Kim, B., & Han, S. Y. (2022). Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea. Pharmacology Research & Perspectives, 10(1).

https://doi.org/10.1002/prp2.910

Sewify, M., Nair, S., Warsame, S., Murad, M., Alhubail, A., Behbehani, K., Al-Refaei, F., & Tiss, A. (2016). Prevalence of urinary tract infection and antimicrobial susceptibility among diabetic patients with controlled and uncontrolled Glycemia in Kuwait. Journal of Diabetes Research, 2016, 1-7.

https://doi.org/10.1155/2016/6573215

Varshney, N., Billups, S. J., Saseen, J. J., & Fixen, C. W. (2021). Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes. Therapeutic Advances in Drug Safety, 12.

https://doi.org/10.1177/2042098621997703

Ferwani, P., Maldar, A., Shah, N., Shah, P., & Chadha, M. (2022). Prevalence of bacterial urinary tract infection among patients with type 2 diabetes mellitus on sodium-glucose cotransporter-2 inhibitors: A prospective real-world setting study. Journal of the ASEAN Federation of Endocrine Societies, 37(2), 5-8.

https://doi.org/10.15605/jafes.037.02.04

Gillani, S. W., Sulaiman, S. A., & Sundram, S. (2012). Prediction and rate of infections in diabetes mellitus patients with diabetes ketoacidosis in Penang, Malaysia. Open Journal of Epidemiology, 02(01), 1-6.

https://doi.org/10.4236/ojepi.2012.21001

Nitzan, O., Elias, M., Chazan, B., & Saliba, W. (2015). Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management. Diabetes, metabolic syndrome and obesity: targets and therapy, 129-136.

https://doi.org/10.2147/DMSO.S51792

Geerlings, S., Fonseca, V., Castro-Diaz, D., List, J., & Parikh, S. (2014). Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria. Diabetes Research and Clinical Practice, 103(3), 373-381.

https://doi.org/10.1016/j.diabres.2013.12.052

Chen, S. L., Jackson, S. L., & Boyko, E. J. (2009). Diabetes mellitus and urinary tract infection: Epidemiology, pathogenesis and proposed studies in animal models. Journal of Urology, 182(6S).

https://doi.org/10.1016/j.juro.2009.07.090

Shah, M. A., Kassab, Y. W., Anwar, M. F., Al Dahoul, H. K., Menon, S., Kaur, H. J., ... & Searan, W. M. (2019). Prevalence and associated factors of urinary tract infections among diabetic patients. Health Science Journal, 13(2), 1-5.

Ijaz, M., Ali, S. A., Khan, S. M., Hassan, M., & Bangash, I. H. (2014). Urinary tract infection in diabetic patients; causative bacteria and antibiotic sensitivity. Journal of Medical Sciences, 22(3), 110-114.

https://jmedsci.com/index.php/Jmedsci/article/view/259

Hirji, I., Guo, Z., Andersson, S. W., Hammar, N., & Gomez-Caminero, A. (2012). Incidence of urinary tract infection among patients with type 2 diabetes in the UK general practice research database (GPRD). Journal of Diabetes and its Complications, 26(6), 513-516.

https://doi.org/10.1016/j.jdiacomp.2012.06.008

Al-Rubeaan, K. A., Moharram, O., Al-Naqeb, D., Hassan, A., & Rafiullah, M. R. (2012). Prevalence of urinary tract infection and risk factors among Saudi patients with diabetes. World Journal of Urology, 31(3), 573-578.

https://doi.org/10.1007/s00345-012-0934-x

Hamdan, H. Z., Kubbara, E., Adam, A. M., Hassan, O. S., Suliman, S. O., & Adam, I. (2015). Urinary tract infections and antimicrobial sensitivity among diabetic patients at Khartoum, Sudan. Annals of Clinical Microbiology and Antimicrobials, 14(1).

https://doi.org/10.1186/s12941-015-0082-4

Fu, A. Z., Iglay, K., Qiu, Y., Engel, S., Shankar, R., & Brodovicz, K. (2014). Risk characterization for urinary tract infections in subjects with newly diagnosed type 2 diabetes. Journal of Diabetes and its Complications, 28(6), 805-810.

https://doi.org/10.1016/j.jdiacomp.2014.06.009

Yu, S., Fu, A. Z., Qiu, Y., Engel, S. S., Shankar, R., Brodovicz, K. G., Rajpathak, S., & Radican, L. (2014). Disease burden of urinary tract infections among type 2 diabetes mellitus patients in the U.S. Journal of Diabetes and its Complications, 28(5), 621-626.

https://doi.org/10.1016/j.jdiacomp.2014.03.012

Saliba, W., Nitzan, O., Chazan, B., & Elias, M. (2015). Urinary tract infections in patients with type 2 diabetes mellitus: Review of prevalence, diagnosis, and management. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 129.

https://doi.org/10.2147/dmso.s51792

Hussain, M., Hussain, A., Rehman, H. U., & Iqbal, J. (2021). Prevalence of Genitourinary infections with sodium glucose Co-transporter-2 (sglt2) inhibitors in patients with type 2 diabetes. Pakistan Journal of Medical and Health Sciences, 15(10), 2804-2807.

https://doi.org/10.53350/pjmhs2115102804